Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, November 12, 2013

Boehringer Sued Over $120M Pay-For-Delay On Stroke Drug

A great stroke association would know all about drugs for stroke and when they come off patent and make sure no hanky-panky is occurring.
http://www.law360.com/articles/488020/boehringer-sued-over-120m-pay-for-delay-on-stroke-drug
Miami-Luken Inc., a wholesaler to pharmacies, accused Boehringer Ingelheim Pharmaceuticals Inc. of orchestrating a $120 million pay-for-delay deal to keep generic versions of its stroke prevention medication off the market, according to a putative class action filed in Pennsylvania federal court Friday.

Miami-Luken says it has been buying Boehringer’s Aggrenox at artificially inflated prices because Boehringer paid off a potential competitor in 2008, agreeing to give it a share of Aggrenox’s profits in exchange for delaying sale of the generic for seven years.

Miami-Luken alleges that...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login


Posted by at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)